ArticleBritish journal of haematology2024
Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis.
2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph
Article in British journal of haematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Real-world Investigation of the Combination of Darafenib or Trametinib and Clofarabine in the Treatment of High-risk, Recurrent, or Refractory Pediatric Patients With Langerhans Cell Histiocytosis.
Modified LCH-III Regimen Versus Modified LCH-III Regimen Combined With Luvometinib in the Treatment of Multisystem Pediatric Langerhans Cell Histiocytosis: A Multicenter, Open-Label, Randomized Controlled Clinical Trial
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- Clofarabine for relapsed/refractory LCH and non-LC histiocytosis.Blood advances · 2026Trial
- Post-hoc analysis of induction failure in pediatric LCH: the JLSG-02 and LCH-12 clinical trials.International journal of hematology · 2026Article
- Efficacy, safety, and relapse outcomes of MAPK inhibitors in pediatric Langerhans cell histiocytosis: A real-world study.International journal of cancer · 2026Article
- Advances in the diagnosis and management of pediatric Langerhans cell histiocytosis and Rosai-Dorfman disease: therapies, biomarkers, and response assessment.Hematology. American Society of Hematology. Education Program · 2025Review
- Refractory Tumorous and Neurodegenerative Histiocytosis Treated With Intra-Arterial Chemotherapy.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Sustained Response to Pan-BRAF Inhibitor Plixorafenib (FORE8394, PLX8394) in a Young Adult With Neurodegenerative Langerhans Cell Histiocytosis.JCO precision oncology · 2025Article
- Article
- [Chinese expert consensus on the diagnosis and treatment of adult Langerhans cell histiocytosis (2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Effective vemurafenib monotherapy for refractory Langerhans cell histiocytosis with sustained results post-withdrawal for over two years: a case report.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 14 institutions in 1 country.
Deevyashali ParekhTexas Children's Cancer Center, Texas Children's Hospital, Houston, Texas, USA.
Howard LinTexas Children's Cancer Center, Texas Children's Hospital, Houston, Texas, USA.
Akanksha BatajooTexas Children's Cancer Center, Texas Children's Hospital, Houston, Texas, USA.
Erin Peckham-GregoryTexas Children's Cancer Center, Texas Children's Hospital, Houston, Texas, USA.
Vivekanudeep KarriTexas Children's Cancer Center, Texas Children's Hospital, Houston, Texas, USA.
Whitney StantonTexas Children's Cancer Center, Texas Children's Hospital, Houston, Texas, USA.
Brooks ScullTexas Children's Cancer Center, Texas Children's Hospital, Houston, Texas, USA.
Ryan FleishmannTexas Children's Cancer Center, Texas Children's Hospital, Houston, Texas, USA.
Nader El-MallawanyTexas Children's Cancer Center, Texas Children's Hospital, Houston, Texas, USA.
Olive S EcksteinTexas Children's Cancer Center, Texas Children's Hospital, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-1895-8810
Zachary D PrudowskyTexas Children's Cancer Center, Texas Children's Hospital, Houston, Texas, USA.
Nitya GulatiTexas Children's Cancer Center, Texas Children's Hospital, Houston, Texas, USA.ORCID https://orcid.org/0000-0001-9243-9544
Jennifer E AgrusaTexas Children's Cancer Center, Texas Children's Hospital, Houston, Texas, USA.
Asra Z AhmedDivision of Hematology/Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Roland ChuDivision of Hematology/Oncology/BMT, Central Michigan University College of Medicine, Children's Hospital of Michigan, Detroit, Michigan, USA.
Matthew S DietzDivision of Pediatric Hematology and Oncology, University of Utah, Primary Children's Hospital, Salt Lake City, Utah, USA.
Stanton C GoldmanPediatric Hematology/Oncology, Medical City Children's Hospital, Dallas, Texas, USA.
Michael D HogartyDivision of Oncology, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Hamayun ImranDepartment of Pediatrics, University of South Alabama, Mobile, Alberta, USA.
Stefanos IntzesDepartment of Pediatric Hematology/Oncology, Sacred Heart Children's Hospital, Spokane, Washington, USA.
Jenny M KimDepartment of Pediatrics, Division of Hematology/Oncology, University of California San Diego School of Medicine, Rady Children's Hospital, San Diego, California, USA.
Lisa M KoppDepartment of Pediatrics, University of Arizona, Mel and Enid Zuckerman College of Public Health, Tucson, Arizona, USA.
Carolyn Fein LevyDivision of Pediatric Hematology/Oncology, Department of Pediatrics, Cohen Children's Medical Center, Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.
Philip NeffChildren's Blood and Cancer Center, The University of Texas at Austin, Dell Children's Medical Center of Central Texas, Austin, Texas, USA.
Pallavi M PillaiJack Martin Division of Pediatric Hematology-Oncology, Jack and Lucy Clark Department of Pediatrics, Mount Sinai Kravis Children's Hospital, New York, New York, USA.
Bryan A SiskDivision of Pediatric Hematology and Oncology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
Deborah E SchiffDepartment of Pediatrics, Division of Hematology/Oncology, University of California San Diego School of Medicine, Rady Children's Hospital, San Diego, California, USA.
Angela D Trobaugh-LotrarioDepartment of Pediatric Hematology/Oncology, Sacred Heart Children's Hospital, Spokane, Washington, USA.
Kelly WalkovichDivision of Pediatric Hematology/Oncology, C.S. Mott Children's Hospital, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Kenneth L McClainTexas Children's Cancer Center, Texas Children's Hospital, Houston, Texas, USA.ORCID https://orcid.org/0000-0003-0725-6263
Carl E AllenTexas Children's Cancer Center, Texas Children's Hospital, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-6625-739X
Baylor College of Medicine · USProvidence Sacred Heart Medical Center · USUniversity of California San Diego · USUniversity of Michigan · USCentral Michigan University · USChildren's Hospital of Philadelphia · USDell Children's Medical Center of Central Texas · USHofstra University · USMedical City Children's Hospital · USMount Sinai Hospital · USPrimary Children's Hospital · USUniversity of Arizona · USUniversity of South Alabama · USWashington University in St. Louis · US
Funding
ERK control of Dendritic Cell Differentiation, Homeostasis and DiseaseR01CA154947 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CARL E ALLEN, MIRIAM MERAD · 2011 to 2026
$7.0MThe Clinical Translational Research Certificate of Added Qualification ProgramT32GM136554 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI Melissa Suter, IGNATIA B VAN DEN VEYVER · 2020 to 2026
$3.0MNCI NIH HHS R01 CA154947NIGMS NIH HHS T32 GM136554NIH HHS CA154947
Abstract
Over 50% of patients with systemic LCH are not cured with front-line therapies, and data to guide salvage options are limited. We describe 58 patients with LCH who were treated with clofarabine. Clofarabine monotherapy was active against LCH in this cohort, including heavily pretreated patients with a systemic objective response rate of 92.6%, higher in children (93.8%) than adults (83.3%). BRAF
Indexed as
ClofarabineHistiocytosis, Langerhans-CellAdenine NucleotidesAdolescentAdultAgedArabinonucleosidesChildChild, PreschoolFemaleHumansInfantMaleMiddle AgedProto-Oncogene Proteins B-rafRecurrenceAdenine NucleotidesArabinonucleosidesBRAF protein, humanClofarabineProto-Oncogene Proteins B-rafclofarabineLangerhans cell histiocytosismyeloid neoplasia
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT07022834ClinicalTrials.gov
NCT07431060ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.